The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City
Open accessAbstract
SARS-COV2 on RT-PCR was therefore significantly lower in cancer patients versus HCWs (30% versus 71%, P 1⁄4 0.04). Importantly, six of the seven serodiagnostic-negative cancer patients had received cytotoxic therapy or major surgical intervention in the previous 4 weeks, compared with none of the five remaining patients (P 1⁄4 0.003). None of these patients died. In this series, 5 of 85 (5.9%) and 13 of 244 (5.4%) cancer patients and HCWs, respectively, had detectable Ab against COVID-19. However, cancer patients had a significantly lower detection rate of SARS-COV2 Ab 15 days or later after symptoms and RT-PCRþ testing. Anti-SARS-COV2 Ab were more often undetectable in patients receiving cancer treatments in the month before testing. Additional studies will be needed to confirm whether immune response to the virus is influenced by recent cancer treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., Jia, P., Guan, H. Q., Peng, L., Chen, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.296 · Cited by 1,498
Risk of COVID-19 for patients with cancer
Xia, Y., Jin, R., Zhao, J., Li, W., & Shen, H. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30150-9 · Cited by 432
COVID-19 infection in cancer patients: early observations and unanswered questions
Oh, W. K. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.297 · Cited by 66
Cited by
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 628
Lee, L. Y. W., Cazier, J.-B., Starkey, T., Briggs, S. E. W., Arnold, R., Bisht, V., Booth, S., Campton, N. A., Cheng, V. W. T., Collins, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30442-3 · Cited by 574
Self-citationCOVID-19 in Immunocompromised Hosts: What We Know So Far
Fung, M., & Babik, J. M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa863 · Cited by 526
Metadata
- Authors
- Miyashita, H., Mikami, T., Chopra, N., Yamada, T., Chernyavsky, S., Rizk, D., & Cruz, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 31
- Issue
- 8
- Pages
- 1088-1089
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3019342843
- Cited by
- 379
- References
- 5
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.